Chemotherapy is “done by THIRD EFFECTIVE” magnetic nanoparticles

Chemotherapy is “done by THIRD EFFECTIVE” magnetic nanoparticles

by

A chemotherapy technique that uses magnetic nanoparticles to heat cancer cells to more than 104 ° F while delivering drugs THIRD is more effective, the study shows

  • Cancer cells are sensitive to heat and can be targeted by magnetic particles
  • It attaches to tumor cells and the magnetic field causes them to heat up
  • This increases their sensitivity to chemo drugs carried by nanoparticles

Joe Pinkstone for Mailonline

Published: |. | Updated:

Chemotherapy could be up to 34 percent more effective thanks to a new technique that combines treatment with magnetic particles that burn cancer cells.

Researchers from University College London have found that a combination of heat and chemical drugs makes the procedure more efficient.

Tiny magnetic nanoparticles attach to cancer cells and also carry chemotherapeutic drugs.

When doctors apply a harmless magnetic field to an area outside the body, it activates the magnetic properties of the nanoparticles and causes them to heat up, heating the trapped cancer cells.

Research reveals that this damages the tumor and makes it more vulnerable to existing drugs.

Chemotherapy has been made up to 34 percent more effective thanks to a new technique that combines treatment with magnetic particles that boil cancer cells (photo photo)

Chemotherapy has been made up to 34 percent more effective thanks to a new technique that combines treatment with magnetic particles that boil cancer cells (photo photo)

The research has so far been tested only in the laboratory, but researchers say the early findings are significant.

Human breast cancer cells, glioblastoma cells (brain cancer) and mouse prostate cancer cells were treated in a test tube with this new technique.

Doxorubicin, a commonly used chemo drug, has been applied to magnetic nanoparticles.

Small magnetic nanoparticles carry a chemotherapeutic drug and also bind to cancerous tumor cells. When doctors apply a harmless magnetic field to an area outside the body, the nanoparticles begin to heat up, warming the cancer cells

Small magnetic nanoparticles carry a chemotherapeutic drug and also bind to cancerous tumor cells. When doctors apply a harmless magnetic field to an area outside the body, the nanoparticles begin to heat up, warming the cancer cells

The results, which have been reviewed and published in the Journal of Materials Chemistry B, show promising results for the experimental method.

Heat and doxorubicin together killed 98 percent of brain cancer cells after 48 hours. The drug killed 73 percent of the cells when applied without heat.

For breast cancer cells, 89 percent of cancers are eliminated by combination, and that alone on the drug drops to 77 percent.

Senior author Professor Nguyen TK Thanh said: ‘Our research shows the enormous potential of combining chemotherapy and heat treatment delivered by magnetic nanoparticles.

‘Although this combination therapy is already approved for the treatment of fast-growing glioblastomas, our results suggest that it may have wider application as a broad-based anti-cancer therapy.

‘This therapy can also reduce the side effects of chemotherapy, ensuring it is more focused on cancer cells rather than a healthy issue. This should be investigated in further preclinical tests. ‘

WHY CAN’T KEMO WORK?

Cancer cells can figure out how to resist chemotherapy.

There are several reasons why this can happen.

Cells that are not killed can mutate and change in response, repair drug-damaged DNA, or develop a mechanism that makes it useless.

Therefore, drug success often relies on the failure of cancer cell regeneration mechanisms.

Cancer cells can produce hundreds of copies of a particular gene, known as gene amplification, which triggers excessive protein production which stops the effectiveness of treatment.

Cancer cells are sometimes able to push the drug out of themselves, using a molecule called a p-glycoprotein.

Since chemotherapy is the first line of treatment, the main concern is when it fails.

Professor Workman, executive director of the Cancer Research Institute, said: ‘The ability of cancer to adapt, develop and become resistant to drugs is the cause of the vast majority of deaths from the disease and the biggest challenge we face in overcoming it.’

.Source